ArticleJournal of clinical microbiology2013
Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents.
Article in Journal of clinical microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Aerobic Isolates from Gestational and Non-Gestational Lactating Bitches (Animals : an open access journal from MDPI · 2021Article
- Genome-wide identification of Streptococcus sanguinis fitness genes in human serum and discovery of potential selective drug targets.Molecular microbiology · 2021Article
- Five-Year Summary ofAntimicrobial agents and chemotherapy · 2017Article
- Endocarditis in left ventricular assist device.Intractable & rare diseases research · 2016Review
- Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013.Antimicrobial agents and chemotherapy · 2015Article
- Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.Antimicrobial agents and chemotherapy · 2015Article
- Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study describes a clinical case of a 71-year-old male with a history of ischemic cardiomyopathy after left ventricular assist device (LVAD) endocarditis caused by methicillin-resistant Staphylococcus epidermidis (MRSE) and a rare linezolid-resistant Streptococcus sanguinis strain (MIC, 32 μg/ml). The patient received courses of several antimicrobial agents, including linezolid for 79 days. The S. sanguinis strain had mutations in the 23S rRNA (T2211C, T2406C, G2576T, C2610T) and an amino acid substitution (N56D) in L22 and exhibited cross-resistance to ribosome-targeting agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.